JP2009536818A - 志賀毒性１型タンパク質に基づく方法および組成物 - Google Patents

志賀毒性１型タンパク質に基づく方法および組成物 Download PDF

Info

Publication number
JP2009536818A
JP2009536818A JP2009506629A JP2009506629A JP2009536818A JP 2009536818 A JP2009536818 A JP 2009536818A JP 2009506629 A JP2009506629 A JP 2009506629A JP 2009506629 A JP2009506629 A JP 2009506629A JP 2009536818 A JP2009536818 A JP 2009536818A
Authority
JP
Japan
Prior art keywords
antibody
stx1
polypeptide
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009506629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536818A5 (https=
Inventor
アンゲラ メルトン−チェルサー
マイケル スミス
アリソン オブライエン
Original Assignee
ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド filed Critical ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Publication of JP2009536818A publication Critical patent/JP2009536818A/ja
Publication of JP2009536818A5 publication Critical patent/JP2009536818A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009506629A 2006-04-20 2007-04-20 志賀毒性１型タンパク質に基づく方法および組成物 Pending JP2009536818A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79391806P 2006-04-20 2006-04-20
PCT/US2007/009799 WO2007124133A2 (en) 2006-04-20 2007-04-20 Methods and compositions based on shiga toxin type 1 protein

Publications (2)

Publication Number Publication Date
JP2009536818A true JP2009536818A (ja) 2009-10-22
JP2009536818A5 JP2009536818A5 (https=) 2011-05-06

Family

ID=38625659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009506629A Pending JP2009536818A (ja) 2006-04-20 2007-04-20 志賀毒性１型タンパク質に基づく方法および組成物

Country Status (7)

Country Link
US (3) US8293245B2 (https=)
EP (2) EP2420246A1 (https=)
JP (1) JP2009536818A (https=)
AU (1) AU2007240614B2 (https=)
CA (1) CA2646319A1 (https=)
MX (1) MX2008013363A (https=)
WO (1) WO2007124133A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
EP1229045A1 (en) 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
EP2420246A1 (en) 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
KR101832499B1 (ko) * 2009-01-23 2018-02-26 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 시가 독소 2형 단백질 기반 방법 및 조성물
JP2012522522A (ja) * 2009-04-06 2012-09-27 ユニバーシティー オヴ サスカチュワン 志賀毒素産生大腸菌感染を処置及び予防するための方法並びに組成物
AU2014285024A1 (en) * 2013-07-03 2016-01-21 Roka Bioscience, Inc. Compositions, kits, and related methods for detecting and/or monitoring Shiga toxin producing Escherichia coli
CN104558167B (zh) * 2014-12-26 2017-12-26 江苏省疾病预防控制中心 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用
EP3749771A1 (en) * 2018-02-07 2020-12-16 Genethon Hybrid regulatory elements
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4573986A (en) * 1984-09-17 1986-03-04 The Procter & Gamble Company Disposable waste-containment garment
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS62292890A (ja) 1986-06-13 1987-12-19 Sanritsu Kikaku Kk 固形潤滑材
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5164298A (en) 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993001831A1 (en) 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
WO1998011229A2 (en) * 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
DK1079856T3 (da) 1998-05-20 2006-12-04 Teijin Ltd Humaniserede antistoffer til genkendelse af verotoxin II samt cellelinie til produktion af samme
CA2348503A1 (en) * 1998-10-30 2000-05-11 James V. Suggs Methods and sensors for detecting or measuring an acid or base
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ATE504312T1 (de) 2003-07-21 2011-04-15 Intervet Int Bv Hybrid-toxine mit shiga-artigen toxin- untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus
EP1694845B8 (en) 2003-11-28 2017-12-20 National Research Council of Canada Anticarcinoma antibodies and uses thereof
CA2555306A1 (en) 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
JP5409014B2 (ja) 2006-02-16 2014-02-05 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 志賀トキソイドキメラタンパク質
EP2420246A1 (en) 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090258010A1 (en) 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
BRPI0720647A2 (pt) 2006-12-29 2014-01-14 Osprey Pharmaceuticals Usa Inc Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos
KR101832499B1 (ko) 2009-01-23 2018-02-26 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 시가 독소 2형 단백질 기반 방법 및 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN7012004572; Ｉｎｆｅｃｔｉｏｎ　ａｎｄ　ｉｍｍｕｎｉｔｙ Ｖｏｌ．５９, 1991, ｐ．７５０-７５７ *
JPN7012004573; ＰＮＡＳ Ｖｏｌ．１０７, 2010, ｐ．１７８８０-１７８８７ *
JPN7012004575; 'Ｅｓｃｈｅｒｉｃｈｉａ　ｃｏｌｉ　Ｏ１５７：Ｈ７　ｓｔｘ１　ｇｅｎｅｓ　ｆｏｒ　ｓｈｉｇａ　ｔｏｘｉｎ　１　ｖａｒｉａｎｔ　Ａ　ｓｕｂｕｎｉｔ，　ｓｈｉｇａ　ｔｏｘｉｎ　１　ｖａｒｉａｎｔ　Ｂ　ｓｕｂ' Ｎｕｃｌｅｏｔｉｄｅ　ｄａｔａｂａｓｅ , 20030702 *

Also Published As

Publication number Publication date
EP2019684A2 (en) 2009-02-04
EP2420246A1 (en) 2012-02-22
WO2007124133A3 (en) 2008-11-27
AU2007240614A1 (en) 2007-11-01
CA2646319A1 (en) 2007-11-01
US20140023652A1 (en) 2014-01-23
US8293245B2 (en) 2012-10-23
WO2007124133A2 (en) 2007-11-01
MX2008013363A (es) 2009-03-26
AU2007240614B2 (en) 2013-09-12
EP2019684A4 (en) 2009-08-26
US20130101591A1 (en) 2013-04-25
US20070292426A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
JP5773886B2 (ja) 志賀毒素タイプ２タンパク質に基づいた方法と組成物
US20140023652A1 (en) Methods and compositions based on shiga toxin type 1 protein
KR910002427B1 (ko) 단일클론 항체의 제조방법 및 이를 함유한 약학 조성물
US10053503B2 (en) Monoclonal antibodies that neutralize anthrax toxins
JP2011512817A (ja) クロストリジウム・ディフィシル胞子に対する抗体及びその使用
Rosenqvist et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis
JP4355786B2 (ja) シュードモナスｖ抗原を用いる免疫化のための方法および組成物
Usuwanthim et al. Murine monoclonal antibodies neutral-izing the cytotoxic activity of diphtheria toxin
Farshad et al. Production and characterization of monoclonal antibodies against Brucella abortus S (99) surface antigens
JP2025149945A (ja) サルモネラの検出方法
Novick Implicating E. coli PAL in the pathogenesis of Gram-Negative sepsis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130605